TZOO
$20.86
(0.97%)
FLWS
$8.16
(6.81%)
ACCO
$5.21
(0.58%)
AUXXF
$0.1
(-4.4%)
ARLP
$28.04
(1.67%)
ALVOF
$3.69
(-0.27%)
AUIAF
$0.25
(-7.65%)
BSET
$14.37
(3.38%)
BXRX
$0
(0%)
BBGI
$8.52
(-4.95%)
BSGM
$1.18
(-4.84%)
BLBX
$1.94
(1.57%)
LUCK
$10.59
(0.28%)
COCP
$2.01
(0%)
CDRO
$6.29
(3.62%)
LODE
$0.29
(-4.97%)
CMTL
$2.66
(0%)
CXW
$22.71
(-0.48%)
LCE:CA
$0.29
(-1.69%)
CMLS
$0.87
(4.57%)
DEFN:CA
$0.17
(-2.94%)
DTGI
$0.01
(-10%)
DRCT
$1.32
(-5.71%)
DLHC
$7.94
(1.93%)
SSP
$2.2
(-4.35%)
EGLE
$62.6
(0%)
ELMGF
$0.03
(-3.27%)
UUUU
$5.07
(-1.93%)
GAME
$0.8
(3.84%)
EVC
$2.3
(-4.17%)
ESK:CA
$0.17
(0%)
GMBL
$0.24
(-13.91%)
EDRY
$11.5
(-2.13%)
ESEA
$33.76
(-2.23%)
GNK
$14.27
(-2.39%)
GEVO
$2.2
(-0.45%)
GRIN
$14.2
(0%)
GTN
$3.21
(-5.31%)
HHS
$5.02
(-2.71%)
INDO
$3.02
(-7.08%)
IPOOF
$1.19
(-3.4%)
KNDI
$1.07
(0.94%)
MSGM
$1.39
(1.46%)
PANL
$5.65
(-0.88%)
PXS
$3.91
(-3.62%)
QMCI
$0.18
(-1.33%)
SALM
$0.58
(3.55%)
SHIP
$7.09
(-0.63%)
TSQ
$9.17
(-1.29%)
TZOO
$20.86
(0.97%)
FLWS
$8.16
(6.81%)

1/16/2025

Rising Mortgage Rates Continue to Challenge Homebuyers and Housing Market Recovery

The average rate on a 30-year mortgage has surged to 7.04%, marking its highest level since May and its fifth consecutive weekly increase. This rise in borrowing costs has left homebuyers facing higher monthly payments, potentially pricing many out of the housing market and prolonging an already sluggish real estate landscape.

0
3 min read

  • Noble Capital Markets Research Morning Call

    Noble Capital Markets Research Morning Call

    Today’s Noble Capital Markets equity research reports, available with free...

    120 min read
  • Electric Revolution: EVs and Hybrids Hit Historic 20% Market Share in US Auto Sales

    3 min read
  • [object Object]
  • The Future of TikTok: U.S. Operations Up for Grabs?

    3 min read

News

1/16/2025

Rising Mortgage Rates Continue to Challenge Homebuyers and Housing Market Recovery

3 min read

Rising Mortgage Rates Continue to Challenge Homebuyers and Housing Market Recovery
1/16/2025

Release – Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

5 min read

Release – Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
1/16/2025

SKYX Platforms (SKYX) – A Step Forward for Its Commercial Distribution Channel

2 min read

SKYX Platforms (SKYX) – A Step Forward for Its Commercial Distribution Channel
1/16/2025

Noble Capital Markets Research Morning Call

120 min read

Noble Capital Markets Research Morning Call

Video Content


  • Ranger Energy Services

    Ranger Energy Services

    Conference Presentation
    1/14/2025

  • P3 Health Partners

    P3 Health Partners

    Conference Presentation
    12/19/2024

  • Unicycive Therapeutics Inc.

    Unicycive Therapeutics Inc.

    Conference Presentation
    12/19/2024

  • Performant

    Performant

    Conference Presentation
    12/18/2024